Year: 2024

MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering

Written by Customer Service on December 10, 2024. Posted in Public Companies.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. The Offering is expected to close on December 11, 2024, subject to the satisfaction of customary closing conditions. MEDIROM intends to use the proceeds...

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Written by Customer Service on December 10, 2024. Posted in Public Companies.

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus. “We’re also presenting three posters that aim to further our understanding of the use of obe-cel in a real-world...

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Written by Customer Service on December 10, 2024. Posted in Public Companies.

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeks Durable clinical responses were associated with improvements in patient-reported measures of fatigue in MDS patients early, and with continued improvement over time Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresLEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

Carbon Dioxide Market is Slated to Develop at a Modest 5.1% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on December 10, 2024. Posted in Mergers And Acquisitions.

Rising use of carbon dioxide in industries like oil recovery, carbonated drinks, and food freezing is driving demand and creating new opportunities for carbon dioxide companies in the future. Westford, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the carbon dioxide market size will attain a value of USD 15.93 billion by 2031, with a CAGR of 5.1% over the forecast period (2024-2031). Increasing use of carbon dioxide in the food and beverage industry and rising adoption of enhanced oil recovery technologies are expected to drive the global carbon dioxide market growth in the future. Rising adoption of carbon capture and storage technologies around the world are also expected to promote the demand for carbon dioxide in the long run. The global carbon dioxide market is expanding rapidly across all regions due to increasing...

Imperial Metals and Mount Polley Served with Notice of Charges Alleging Violations of the Fisheries Act

Written by Customer Service on December 10, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) and its subsidiary Mount Polley Mining Corporation, along with engineering firm Wood Canada Limited, have been charged with alleged violations of the federal Fisheries Act, arising from the failure of the Tailings Storage Facility at the Mount Polley Mine more than 10 years ago in August of 2014. The charges are outlined in an indictment filed with the Supreme Court of British Columbia on December 6, 2024 which the Company received today. As this matter is before the courts, the Company does not intend to make further public statements. About Imperial Imperial is a Vancouver based exploration, mine development and operating company with holdings that include the Mount Polley mine (100%), the Huckleberry mine (100%),...

VERSES Closes Third Tranche of LIFE Offering

Written by Customer Service on December 10, 2024. Posted in Public Companies.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed the third tranche of its previously announced non-brokered private placement (the “LIFE Offering”) of units of the Company (the “LIFE Units”) for gross proceeds in this third tranche of $770,000 from a single investor. The first tranche of the LIFE Offering closed on November 8, 2024, for aggregate gross proceeds of $2,903,850 and the second tranche of the LIFE Offering closed on November 15, 2024, for aggregate gross proceeds of $512,800. Pursuant to the third tranche of the LIFE Offering, the Company issued 1,540,000 LIFE Units at a price of $0.50 per LIFE...

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Written by Customer Service on December 10, 2024. Posted in Public Companies.

89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 months Results add to the overall survival (OS) benefit recently reported making CARVYKTI® the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma Landmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionSOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher...

Cassius Ventures Ltd. Announces Arrangements to Address Mailing Delays as a Result of The Canada Post Strike

Written by Customer Service on December 10, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) — Cassius Ventures Ltd. (the “Company”) reports that, due to the ongoing Canada Post postal strike, delivery of the notice of meeting, information circular and proxy and voting information forms (the “Meeting Materials”) for the Company’s upcoming annual general meeting (the “Meeting”), to be held at 595 Burrard Street, Suite 3083, Vancouver, British Columbia on December 30, 2024 at 11 a.m. (PST), will be significantly delayed until the Canada Post postal strike is resolved and therefore, shareholders may not receive physical copies of the Meeting Materials in advance of the Meeting. The Meeting will be held for the following purposes:1. to receive the financial statements of the Company for the fiscal year ended October 31, 2023, together with the auditor’s report...

Sirios Resources Announces Closing of a Second Tranche of $849,000 of its Flow-Through Private Placement

Written by Customer Service on December 10, 2024. Posted in Public Companies.

MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) — SIRIOS RESOURCES SIRIOS INC. (TSX-V: SOI) (the “Corporation”) announces the closing of the second tranche of its non-brokered private placement (the “Offering“), through the issuance of 12,128,574 common shares in the capital of the Corporation (the “Shares“), at a price of $0.07 per-Share. The aggregate gross proceeds for this second tranche are $849,000. The Shares were issued as “flow-through shares” pursuant to section 66(15) of the Income Tax Act (Canada) and section 359.1 of the Taxation Act (Quebec). The qualifying expenditures will be renounced in favour of the subscribers with an effective date no later than December 31, 2024. The gross proceeds from the sale of Shares will be used by the Corporation to incur eligible “Canadian...

ThreeD Capital Inc. Announces Unaudited November 30, 2024 Net Asset Value Per Share – $0.77

Written by Customer Service on December 10, 2024. Posted in Public Companies.

TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that at November 30, 2024, its unaudited net asset value per share (“NAV”) was $0.77. This announcement is made based on ThreeD’s established practice of releasing NAV on a monthly basis as part of the Company’s ongoing response to shareholder interest in receiving periodic information. NAV is calculated based on unaudited month-end financial information. Use of Non-GAAP Financial Measures: This press release contains references to NAV or “net asset value per share” which is a non-GAAP financial measure. NAV is calculated as the value of total assets less the...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals